Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Benchmark Maintains Buy on Plexus, Raises Price Target to $105

Benchmark Maintains Buy on Plexus, Raises Price Target to $105

Benchmark analyst David Williams maintains Plexus (NASDAQ:PLXS) with a Buy and raises the price target from $101 to $105.

August 29, 2022

1 minute read

Benchmark analyst David Williams maintains Plexus (NASDAQ:PLXS) with a Buy and raises the price target from $101 to $105.

HSBC, BNP Face Potential Fines In South Korea Over Allegations Of Naked Short Selling

December 21, 3:00 AM

The Financial Services Commission (FSC) is recommending a minimum fine of 10 billion won ($7.67 million) each on the two banking giants.

March 17, 8:32 AM

Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and lowers the price target from $55 to $48.

May 29, 2:01 PM

In the latest quarter, 7 analysts provided ratings for Globus Medical (NYSE:GMED), showcasing a mix of bullish and…

November 29, 12:15 PM

https://www.wsj.com/articles/amc-networks-ceo-christina-spade-steps-down-after-less-than-three-months-11669729033?st=e8t2l8drbgsfli3